# Celcuity Block Pam. Unlock Tomorrow

> Markdown mirror of DialtoneApp's public top-site detail page for `celcuity.com`.

URL: https://dialtoneapp.com/top-sites/celcuity.com/index.md
Canonical HTML: https://dialtoneapp.com/top-sites/celcuity.com

## Summary

- Domain: `celcuity.com`
- Website: https://celcuity.com
- Description: ai readable | score 20 | purchase read only
- Label: ai_readable
- Payment surface: Not available
- Purchase boundary: read_only
- Control boundary: unknown
- Rank: 683695

## robots

~~~text
User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php
Crawl-delay: 10

Sitemap: https://www.celcuity.com/sitemap.xml
Sitemap: https://www.celcuity.com/sitemap.rss
~~~

## llms

~~~text
Generated by All in One SEO v4.9.6.2, this is an llms.txt file, used by LLMs to index the site.

# Celcuity

## Sitemaps

- [XML Sitemap](https://www.celcuity.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Developing first-in-class therapeutics  using a 3rd generation diagnostic platform](https://www.celcuity.com/developing-first-in-class-therapeutics-using-a-3rd-generation-diagnostic-platform/) - Molecular tests can’t detect the complex oncogenic activity driving many cancers. CELsignia, our 3rd generation cellular analysis platform, unravels the complex oncogenic activity molecular tests cannot detect. This enables us to discover previously undetectable cancer drivers and new therapeutic options for cancer patients. With the unique tumor insights CELsignia generates, we can identify new applications

## Pages

- [Block Pam. Unlock Tomorrow](https://www.celcuity.com/) - Targeted therapies only work when inhibiting the target pathway disrupts the oncogenic process. Celcuity’s platform provides unparalleled insights into oncogenic pathways. We harness these insights to develop new targeted therapies for cancer patients. Our lead candidate is gedatolisib, a pan-PI3K, mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (PAM) pathway.
- [About](https://www.celcuity.com/about/)
- [VIKTORIA-1: Breast Cancer](https://www.celcuity.com/clinical-trials/viktoria-1/)
- [Careers](https://www.celcuity.com/careers/)
- [EU/EEA/UK Healthcare Professional Privacy Notice](https://www.celcuity.com/eu-eea-uk-healthcare-professional-privacy-notice/) - Privacy Policy Consumer Health Data Privacy Policy EU/EEA/UK Healthcare Professional Privacy Notice
- [Terms of Use](https://www.celcuity.com/terms-of-use/) - Last Updated: January 20, 2026 Welcome to www.celcuity.com (the “Website”) which is owned/operated by Celcuity Inc. (“Celcuity”, “us” or “we”). By using the Website, you agree to be bound and abide by these Website Terms of Use (“Terms”) and our Privacy Policy, which is located in our Privacy Center and hereby incorporated by reference. If
- [Consumer Health Data Privacy Policy](https://www.celcuity.com/consumer-health-data-privacy-policy/) - Privacy Policy Consumer Health Data Privacy Policy EU/EEA/UK Healthcare Professional Privacy Notice Effective Date: January 20, 2026 This Consumer Health Data Privacy Policy applies to “Consumer Health Data” as that term has been defined under applicable Consumer Health Data laws. Any term appearing in this Consumer Health Data Privacy Policy that has been defined under
- [Privacy Center](https://www.celcuity.com/privacy-center/) - Privacy Policy Consumer Health Data Privacy Policy EU/EEA/UK Healthcare Professional Privacy Notice
- [test](https://www.celcuity.com/test/)
- [Open Positions](https://www.celcuity.com/open-positions/) - 18 jobsAll departmentsClinical DevelopmentCommercialGeneral & AdministrativePharmaceutical Development and OperationsQuality Assurance and Process DevelopmentR & D and Laboratory OperationsAll officesMinneapolis, MNRemoteClinical DevelopmentAssociate Director, Clinical ScientistRemoteDirector, Medical Science Liaison, CarolinasRemoteDirector, Medical Science Liaison, North Central (Chicago, Illinois)RemoteDirector, Safety ScienceRemoteSenior Manager, Clinical Data ManagementRemoteSenior Manager/Associate Director, Statistical ProgrammingRemoteSenior Medical DirectorRemoteCommercialAssociate Director, Field OperationsRemoteDirector, Strategic AccountsRemoteGeneral & AdministrativeSenior Manager,
- [Investors](https://www.celcuity.com/investors/)
- [IR alerts](https://www.celcuity.com/ir-alerts/)
- [Stock Chart](https://www.celcuity.com/stock-chart/)
- [Our Pipeline](https://www.celcuity.com/our-pipeline/)
- [Science](https://www.celcuity.com/science/)
- [VIKTORIA-2: Breast Cancer](https://www.celcuity.com/clinical-trials/viktoria-2/)
- [CELC-G-201: Prostate Cancer](https://www.celcuity.com/clinical-trials/celc-g-201-prostate-cancer/)
- [Accessibility Statement](https://www.celcuity.com/accessibility-statement/) - Last Updated September 1, 2022 Compliance status We firmly believe that the internet should be available and accessible to anyone and are committed to providing a website that is accessible to the broadest possible audience, regardless of ability. To fulfill this, we aim to adhere as strictly as possible to the World Wide Web Consortium’s
- [Publications](https://www.celcuity.com/science/publications/)
- [A Breast Cancer Study <h2 style="color:#fff; font-size:30px">2nd line treatment for HR+/HER2- advanced breast cancer</h2>](https://www.celcuity.com/viktoria-1/) - A Breast Cancer Study 2nd line treatment for HR+/HER2- advanced breast cancer
- [Gedatolisib](https://www.celcuity.com/gedatolisib/)
- [2020 ASCO Abstract](https://www.celcuity.com/science/publications/2020-asco-abstract/) - 2020 ASCO Annual Meeting Test measuring signaling activity in live patient tumor cells identifies PI3KCA WT patients who may benefit from PIK3 inhibitorsLance G Laing, Salmaan Khan, Ian A MacNeil, Catherine Kuzmicki, Benjamin Rich, Abhay Shukla, Kelly Brass, Brian Sullivan; Celcuity Inc. Minneapolis, MN Background: Biological factors other than PIK3CA status, such as aberrant GPCR-linked
- [2020 AACR Abstract](https://www.celcuity.com/science/publications/2020-aacr-abstract/) - Background: Sub-groups of breast, lung, and colon cancer patients with genetic variants associated with dysregulated ErbB signaling benefit from treatment with ErbB targeted therapies. No sub-groups of ovarian cancer patients with actionable ErbB genetic variants have yet been found. Measurement of biological factors other than genetic variants, such as ErbB signaling activity, may identify ovarian cancer patients likely to benefit from ErbB targeted therapies.
- [Biopharma collaborations](https://www.celcuity.com/science/publications/biopharma-collaborations/) - Expanding eligible patient populations for targeted therapies We are partnering with pharmaceutical companies to provide companion diagnostics for their existing or investigational targeted therapies. CELsignia offers a new way to identify patients eligible for targeted therapies. CELsignia tests diagnose dysregulated signaling cancer drivers that molecular based approaches cannot detect. Why? The nature of cell signaling
- [Preclinical Study 2](https://www.celcuity.com/science/publications/preclinical-study-2/) - Study 2: Tumor xenograft study vs. CELsignia signaling analysis using c-Met and ErbB targeted therapies The HCC1954 breast cancer cell line was found by the CELsignia Test to have abnormal HER2, HER1, and c-Met pathways. The efficacy of different HER family and c-Met as single agents and in combination was also determined ex vivo.
- [Preclinical Study 1](https://www.celcuity.com/science/publications/preclinical-study-1/) - Study 1: Anti-HER2 therapies treating abnormal HER2 signaling in HER2-negative xenograft tumor models Previous clinical trials have indicated that there is a weak correlation between HER2 expression levels and HER2 targeted therapy benefit. To evaluate whether HER2-negative tumors with abnormal HER2 signaling may respond to anti-HER2 drugs, H2073 and BT483 cell lines were studied in
- [Clinical Trials](https://www.celcuity.com/clinical-trials/) - CELsignia FACT 1: Herceptin ® + Perjeta ® + AC-THP in Early-Stage HER2-Negative Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT03412643/FB-12) FACT 2: Nerlynx ® + Paclitaxel + Carboplatin in Early-Stage Triple-Negative Breast Cancer Patients Selected with the CELsignia HER2 Activity Test (NCT03812393) FACT 3: Xalkori ® + Vizimpro ® in Metastatic

## Publications

- [Synergistic Efficacy of Gedatolisib and Darolutamide in Prostate Cancer to Overcome Resistance to Androgen-Targeted Therapy](https://www.celcuity.com/publication/synergistic-efficacy-of-gedatolisib-and-darolutamide-in-prostate-cancer-to-overcome-resistance-to-androgen-targeted-therapy/)
- [VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer](https://www.celcuity.com/publication/viktoria-1-trial-of-gedatolisib-plus-fulvestrant-with-or-without-palbociclib-in-hormone-receptor-positive-her2-pik3ca-wild-type-advanced-breast-cancer/)
- [Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, plus fulvestrant with or without palbociclib for second-line treatment of patients with HR+/HER2-/ PIK3CA-WT advanced breast cancer: updated results from the randomized, phase 3 VIKTORIA-1 trial](https://www.celcuity.com/publication/gedatolisib-a-multitarget-pi3k-akt-mtor-inhibitor-plus-fulvestrant-with-or-without-palbociclib-for-second-line-treatment-of-patients-with-hr-her2-pik3ca-wt-advanced-breast-cancer-updated-results/)
- [Functional analysis of gedatolisib combined with fulvestrant and/or palbociclib in breast cancer cell models  adapted to estrogen receptor and/or CDK4/6 inhibitors](https://www.celcuity.com/publication/functional-analysis-of-gedatolisib-combined-with-fulvestrant-and-or-palbociclib-in-breast-cancer-cell-models-adapted-to-estrogen-receptor-and-or-cdk4-6-inhibitors/)
- [Phase 1/2 Study of Gedatolisib in Combination with Darolutamide in Metastatic Castration-Resistant  Prostate Cancer](https://www.celcuity.com/publication/phase-1-2-study-of-gedatolisib-in-combination-with-darolutamide-in-metastatic-castration-resistant-prostate-cancer/)
- [Gedatolisib Plus Fulvestrant, With & Without Palbociclib, vs Fulvestrant in Patients With HR+/HER2-/<em>PIK3CA</em> Wild-Type Advanced Breast Cancer: First Results from VIKTORIA-1](https://www.celcuity.com/publication/gedatolisib-plus-fulvestrant-with-without-palbociclib-vs-fulvestrant-in-patients-with-hr-her2-pik3ca-wild-type-advanced-breast-cancer-first-results-from-viktoria-1/)
- [Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor, Clin Cancer Res; 17(10); 3193–203, 2011](https://www.celcuity.com/publication/antitumor-efficacy-of-pki-587-a-highly-potent-dual-pi3k-mtor-kinase-inhibitor-clin-cancer-res-1710-3193-203-2011/)
- [First-in human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res; 21(8) April 15, 2015](https://www.celcuity.com/publication/first-in-human-study-of-pf-05212384-pki-587-a-small-molecule-intravenous-dual-inhibitor-of-pi3k-and-mtor-in-patients-with-advanced-cancer-clin-cancer-res-218-april-15-2015/)
- [A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer, Gynecologic Oncology 142, 62–69, 2016](https://www.celcuity.com/publication/a-randomized-phase-ii-non-comparative-study-of-pf-04691502-and-gedatolisib-pf-05212384-in-patients-with-recurrent-endometrial-cancer-gynecologic-oncology-142-62-69-2016/)
- [Subgroup of ovarian cancer patients with hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors](https://www.celcuity.com/publication/subgroup-of-ovarian-cancer-patients-with-hyperactive-ras-network-signaling-identified-dynamic-pathway-activity-test-identifies-patients-that-may-benefit-from-pi3k-mtor-or-pi3k-mtor-bcl-inhibitors/)
- [Subgroup of HER2-negative breast cancer patients with hyperactive RAS network signaling identified: dynamic pathway activity test identifies patients that may benefit from PI3K/mTOR or PI3K/mTOR/BCL inhibitors](https://www.celcuity.com/publication/subgroup-of-her2-negative-breast-cancer-patients-with-hyperactive-ras-network-signaling-identified-dynamic-pathway-activity-test-identifies-patients-that-may-benefit-from-pi3k-mtor-or-pi3k-mtor-bcl-i/)
- [Phase I dose-escalation study of the dual PI3K-mTORC1/2 inhibitor gedatolisib in combination with paclitaxel and carboplatin in patients with advanced solid tumors. Clin Cancer Res;27:5012–9, 2021](https://www.celcuity.com/publication/phase-i-dose-escalation-study-of-the-dual-pi3k-mtorc1-2-inhibitor-gedatolisib-in-combination-with-paclitaxel-and-carboplatin-in-patients-with-advanced-solid-tumors-clin-cancer-res275012-9/)
- [Phase II study of trastuzumab biosimilar (Herzuma®) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy: KM-10A (KCSG BR 18-13) interim analysis](https://www.celcuity.com/publication/phase-ii-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-her-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-her-2-directed-chemotherapy-km-10a-k/)
- [Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer](https://www.celcuity.com/publication/phase-ib-expansion-study-of-gedatolisib-in-combination-with-palbociclib-and-endocrine-therapy-in-women-with-er-metastatic-breast-cancer/)
- [A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British Journal of Cancer 2022](https://www.celcuity.com/publication/a-phase-1b-open-label-study-of-gedatolisib-pf-05212384-in-combination-with-other-anti-tumour-agents-for-patients-with-advanced-solid-tumours-and-triple-negative-breast-cancer-british-journal-of-can/)
- [Updated results of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Subgroup analysis by PIK3CA mutation status](https://www.celcuity.com/publication/updated-results-of-a-phase-1b-study-of-gedatolisib-plus-palbociclib-and-endocrine-therapy-in-women-with-hormone-receptor-positive-advanced-breast-cancer-subgroup-analysis-by-pik3ca-mutation-status/)
- [A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)](https://www.celcuity.com/publication/a-phase-3-study-of-gedatolisib-plus-fulvestrant-with-and-without-palbociclib-in-patients-with-hr-her2-advanced-breast-cancer-previously-treated-with-a-cdk4-6-inhibitor-plus-a-non-steroidal-aromatase-2/)
- [Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models differing in PI3K or PTEN mutational status](https://www.celcuity.com/publication/therapeutic-effect-of-gedatolisib-a-pan-pi3k-mtor-inhibitor-on-prostate-cancer-models-differing-in-pi3k-or-pten-mutational-status/)
- [A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a non-steroidal aromatase inhibitor (VIKTORIA-1)](https://www.celcuity.com/publication/a-phase-3-study-of-gedatolisib-plus-fulvestrant-with-and-without-palbociclib-in-patients-with-hr-her2-advanced-breast-cancer-previously-treated-with-a-cdk4-6-inhibitor-plus-a-non-steroidal-aromatase/)
- [Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on gynecological cancer models regardless of their PI3K pathway mutational status](https://www.celcuity.com/publication/gedatolisib-a-well-tolerated-pan-pi3k-mtor-inhibitor-exhibits-potent-therapeutic-effects-on-gynecological-cancer-models-regardless-of-their-pi3k-pathway-mutational-status/)
- [Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: updated results in treatment naïve patients](https://www.celcuity.com/publication/phase-1b-study-of-gedatolisib-plus-palbociclib-and-endocrine-therapy-in-women-with-hormone-receptor-positive-advanced-breast-cancer-updated-results-in-treatment-naive-patients/)
- [Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency & efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models](https://www.celcuity.com/publication/gedatolisib-a-pan-pi3k-mtor-inhibitor-shows-superior-potency-efficacy-relative-to-other-pi3k-akt-mtor-pathway-inhibitors-in-breast-cancer-models/)
- [Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study](https://www.celcuity.com/publication/gedatolisib-in-combination-with-palbociclib-and-endocrine-therapy-in-women-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer-results-from-the-dose-expansion-groups-of-an-open-label/)
- [Gedatolisib shows superior potency and efficacy versus single-node PI3K/AKT/mTOR inhibitors in breast cancer models](https://www.celcuity.com/publication/gedatolisib-shows-superior-potency-and-efficacy-versus-single-node-pi3k-akt-mtor-inhibitors-in-breast-cancer-models/)
- [Assessments of prostate cancer cell functions highlight differences between a pan-PI3K/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K/AKT/mTOR pathway](https://www.celcuity.com/publication/assessments-of-prostate-cancer-cell-functions-highlight-differences-between-a-pan-pi3k-mtor-inhibitor-gedatolisib-and-single-node-inhibitors-of-the-pi3k-akt-mtor-pathway/)
- [Functional Assessments of Gynecologic Cancer Models Highlight Differences Between Single-Node Inhibitors of the PI3K/AKT/mTOR Pathway and a Pan-PI3K/mTOR Inhibitor, Gedatolisib](https://www.celcuity.com/publication/functional-assessments-of-gynecologic-cancer-models-highlight-differences-between-single-node-inhibitors-of-the-pi3k-akt-mtor-pathway-and-a-pan-pi3k-mtor-inhibitor-gedatolisib/)
- [Mechanism of action of gedatolisib in combination with fulvestrant and/or palbociclib in estrogen receptor positive breast cancer models](https://www.celcuity.com/publication/mechanism-of-action-of-gedatolisib-in-combination-with-fulvestrant-and-or-palbociclib-in-estrogen-receptor-positive-breast-cancer-models/)
- [Different effects of gedatolisib versus single-node PI3K/AKT/mTOR pathway inhibitors on breast cancer cell metabolic functions](https://www.celcuity.com/publication/different-effects-of-gedatolisib-versus-single-node-pi3k-akt-mtor-pathway-inhibitors-on-breast-cancer-cell-metabolic-functions/)
- [Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy](https://www.celcuity.com/publication/overall-survival-in-patients-with-hr-her2-advanced-breast-cancer-treated-in-a-phase-1b-trial-evaluating-gedatolisib-in-combination-with-palbociclib-and-endocrine-therapy-2/)
- [Functional analysis of the PI3K/AKT/mTOR pathway inhibitor, gedatolisib, plus fulvestrant with and without palbociclib in breast cancer models](https://www.celcuity.com/publication/functional-analysis-of-the-pi3k-akt-mtor-pathway-inhibitor-gedatolisib-plus-fulvestrant-with-and-without-palbociclib-in-breast-cancer-models/)
- [Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy](https://www.celcuity.com/publication/overall-survival-in-patients-with-hr-her2-advanced-breast-cancer-treated-in-a-phase-1b-trial-evaluating-gedatolisib-in-combination-with-palbociclib-and-endocrine-therapy/)
- [Gedatolisib combined with palbociclib and letrozole in patients with no prior systemic therapy for hormone receptor–positive, HER2-negative advanced breast cancer](https://www.celcuity.com/publication/gedatolisib-combined-with-palbociclib-and-letrozole-in-patients-with-no-prior-systemic-therapy-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer/)
- [Dynamic real-time signaling profiles of live primary cells characterize the response of PI3K and MAPK pathways in HER2+ breast cancer cells to attenuation with lapatinib: Tests of reproducibility of method](https://www.celcuity.com/publication/dynamic-real-time-signaling-profiles-of-live-primary-cells-characterize-the-response-of-pi3k-and-mapk-pathways-in-her2-breast-cancer-cells-to-attenuation-with-lapatinib-tests-of-reproducibility-of-m/)
- [Profiling of signaling pathways in live tumor cells to assess drug mechanism of action: A method to predict drug efficacy in a patient](https://www.celcuity.com/publication/profiling-of-signaling-pathways-in-live-tumor-cells-to-assess-drug-mechanism-of-action-a-method-to-predict-drug-efficacy-in-a-patient/)
- [New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit from anti-HER2 therapy](https://www.celcuity.com/publication/new-method-to-measure-functional-her2-driven-signaling-activity-in-primary-tumor-cells-identifies-her2-negative-breast-cancers-with-abnormal-her2-signaling-activity-new-group-of-patients-may-benefit/)
- [Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activity](https://www.celcuity.com/publication/quantification-of-her2-driven-signaling-her2s-inhibition-of-four-different-anti-her2-drugs-tested-ex-vivo-in-live-primary-her2-negative-breast-cancer-cell-samples-with-abnormal-her2-signaling-activi/)
- [Inhibition of abnormal HER2-driven signaling by two HER2 targeted antibody drugs tested ex vivo in live primary HER2- breast cancer cell samples and HER2+ cell lines](https://www.celcuity.com/publication/inhibition-of-abnormal-her2-driven-signaling-by-two-her2-targeted-antibody-drugs-tested-ex-vivo-in-live-primary-her2-breast-cancer-cell-samples-and-her2-cell-lines/)
- [Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study](https://www.celcuity.com/publication/measuring-functional-her2-driven-signaling-status-ex-vivo-to-predict-response-to-her2-therapy-results-from-a-mouse-breast-tumor-xenograft-study/)
- [Use of a functional signal profiling test to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit from anti-HER2 therapy](https://www.celcuity.com/publication/use-of-a-functional-signal-profiling-test-to-determine-the-prevalence-of-abnormal-her2-driven-signaling-activity-in-the-her2-negative-breast-cancer-patient-population-new-patient-group-may-benefit-fr/)
- [A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormal amplified HER2 signaling activity. Oncotarget. 2016 Oct 5;7(48) 78577-78590](https://www.celcuity.com/publication/a-functional-signal-profiling-test-for-identifying-a-subset-of-her2-negative-breast-cancers-with-abnormal-amplified-her2-signaling-activity-oncotarget-2016-oct-5748-78577-78590/)
- [Development of a test that measures real-time HER2 signaling activity in live breast cancer cell lines and primary cells. BMC Cancer. 2017 March 17:199](https://www.celcuity.com/publication/development-of-a-test-that-measures-real-time-her2-signaling-activity-in-live-breast-cancer-cell-lines-and-primary-cells-bmc-cancer-2017-march-17199/)
- [A phase 2 study of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in HER2-negative breast cancer patients with abnormal HER2-driven signaling transduction (NCT03412643)](https://www.celcuity.com/publication/a-phase-2-study-of-neoadjuvant-chemotherapy-plus-trastuzumab-and-pertuzumab-in-her2-negative-breast-cancer-patients-with-abnormal-her2-driven-signaling-transduction-nct03412643/)
- [Test measuring signaling activity in live patient tumor cells identifies PI3KCA WT patients who may benefit from PIK3 inhibitors](https://www.celcuity.com/publication/test-measuring-signaling-activity-in-live-patient-tumor-cells-identifies-pi3kca-wt-patients-who-may-benefit-from-pik3-inhibitors/)
- [Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer](https://www.celcuity.com/publication/live-tumor-cell-functional-analysis-and-a-xenograft-model-find-co-activated-c-met-and-erbb-signaling-in-her2-negative-breast-cancer/)
- [Sub-group of HER2- breast cancer patients with hyperactive and co-involved c-Met and ErbB pathways identified: functional signal profiling test identifies patient group that may benefit from c-Met and pan-HER combination therapy](https://www.celcuity.com/publication/sub-group-of-her2-breast-cancer-patients-with-hyperactive-and-co-involved-c-met-and-erbb-pathways-identified-functional-signal-profiling-test-identifies-patient-group-that-may-benefit-from-c-met-and/)
- [Evaluating contribution of hyperactive c-Met and ErbB signaling to tumor progression in mouse breast tumor xenografts: an in vivo study of c-Met and ErbB targeted therapies](https://www.celcuity.com/publication/evaluating-contribution-of-hyperactive-c-met-and-erbb-signaling-to-tumor-progression-in-mouse-breast-tumor-xenografts-an-in-vivo-study-of-c-met-and-erbb-targeted-therapies/)
- [Evaluation of pan-HER and c-MET inhibitors tested ex vivo in live primary HER2- breast cancer cells with hyperactive c-MET and ErbB family signaling](https://www.celcuity.com/publication/evaluation-of-pan-her-and-c-met-inhibitors-tested-ex-vivo-in-live-primary-her2-breast-cancer-cells-with-hyperactive-c-met-and-erbb-family-signaling/)
- [Sub-Group of PIK3CA WT breast cancer patients have hyperactive S1P and LPA signaling tumors responsive to PI3K inhibitors: functional signaling test identifies new patient group who may benefit from PI3K inhibitors](https://www.celcuity.com/publication/sub-group-of-pik3ca-wt-breast-cancer-patients-have-hyperactive-s1p-and-lpa-signaling-tumors-responsive-to-pi3k-inhibitors-functional-signaling-test-identifies-new-patient-group-who-may-benefit-from-p/)
- [Hyperactive c-Met and ErbB signaling detected in a sub-group of ovarian patient tumors: Patient sub-group may benefit from c-Met and pan-HER combination therapy](https://www.celcuity.com/publication/hyperactive-c-met-and-erbb-signaling-detected-in-a-sub-group-of-ovarian-patient-tumors-patient-sub-group-may-benefit-from-c-met-and-pan-her-combination-therapy/)
- [Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy. Cell Communication and Signaling, 20:4, 2022](https://www.celcuity.com/publication/functional-signaling-test-identifies-her2-negative-breast-cancer-patients-who-may-benefit-from-c-met-and-pan-her-combination-therapy-cell-communication-and-signaling-204-2022/)
- [New HER2‐negative breast cancer subtype responsive to anti‐HER2 therapy identified. Journal of Cancer Research and Clinical Oncology 2020;146:605-619](https://www.celcuity.com/publication/new-her2‐negative-breast-cancer-subtype-responsive-to-anti‐her2-therapy-identified-journal-of-cancer-research-and-clinical-oncology-2020146605-619/)
- [Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 50-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26 (PKI-587), a Highly Efficacious Dual Inhibitor. J. Med. Chem. 2010, 53, 6, 2636–2645](https://www.celcuity.com/publication/bismorpholino-135-triazine-derivatives-potent-adenosine-50-triphosphate-competitive-phosphatidylinositol-3-kinase-mammalian-target-of-rapamycin-inhibitors-discovery-of-compound-26-pki-587-a-h/)

## Jobs

- [Associate Director, R&D Laboratory](https://www.celcuity.com/jobs/associate-director-rd-laboratory/) - POSITION SUMMARY: Reporting to the Chief Science Officer/Technical Supervisor, the Associate Director, R&D Laboratory is responsible for the overall operation and administration of a CLIA-certified, CAP-accredited, GLP high-complexity clinical laboratory. This role will lead laboratory operations, ensure regulatory compliance, and drive high-quality test development and execution within the R&D environment. PRIMARY RESPONSIBILITIES AND DUTIES: Laboratory
- [Director or Senior Director, API Development](https://www.celcuity.com/jobs/director-or-senior-director-api-development/) - Position Summary: We are seeking a Director or Senior Director, API Development, who will report to the Executive Director of Pharmaceutical Development. You will be the technical expert for current API synthesis production and will lead creation, optimization, and management of additional API entities as part of new compound/formulation development activities. Responsibilities: Provide leadership and
- [Director, Medical Science Liaison, North Central (Chicago, Illinois)](https://www.celcuity.com/jobs/director-medical-science-liaison-north-central-chicago-illinois/) - Location: North Central (Minnesota, Iowa, Nebraska, South Dakota, North Dakota, Kansas, Missouri) This region does not include Illinois, but the prospective new hire can reside in the Chicagoland area. Position Summary: We are seeking a Director, MSL who will report to the Senior Director, Western US Field Medical. The Director, MSL will be responsible
- [Director, Medical Science Liaison, Carolinas](https://www.celcuity.com/jobs/director-medical-science-liaison-carolinas/) - Location: Carolinas (North Carolina, South Carolina, Virginia, West Virginia, Tennessee, and Kentucky) Position Summary: We are seeking a Director, MSL who will report to the Senior Director, Eastern US Field Medical. The Director, MSL will be responsible for scientific exchange with Health Care Providers (HCPs) and key decision makers (managed care, payers, formulary committees, etc.) on Celcuity’s
- [Associate Scientist, Cell Signaling and Assay Development](https://www.celcuity.com/jobs/associate-scientist-cell-signaling-and-assay-development/) - POSITION SUMMARY: Reporting to the Director, Tissue or Assay / Laboratory Manager, the Associate Scientist will play a key role in the development, validation, and execution of live-cell assays supporting translational oncology research. This individual will contribute to advancing precision medicine by characterizing cell signaling pathways and ensuring the generation of high-quality, reproducible data in
- [Associate Director, Field Operations](https://www.celcuity.com/jobs/associate-director-field-operations/) - Position Summary: Responsible for different aspects of the day-to-day operations of Celcuity’s field teams including Sales, Market Access, Marketing and Medical Affairs. Responsible for working with field team and external vendors to implement, maintain and provide support for CRM. Responsible for CRM analytics for internal stakeholders. Manages field enablement programs including credentialing, vehicle reimbursement and
- [Associate Director, Clinical Scientist](https://www.celcuity.com/jobs/associate-director-clinical-scientist/) - Position Summary: We are seeking a Associate Director, Clinical Scientist, who will report to the Executive Director, Clinical Science. You will be responsible for the execution of Clinical Development goals through collaboration with and support of Medical Directors/Physicians and Clinical Development department activities. The Clinical Scientist will represent the Clinical Science group on various teams/sub-teams
- [Senior Quality Assurance Auditor](https://www.celcuity.com/jobs/senior-quality-assurance-auditor/) - Title: Senior Auditor Location: Remote Position Summary: We are seeking a Senior Auditor who will report into the Director, Quality Assurance. The Senior Auditor is a technical expert responsible for independently planning, leading, and executing complex internal and external GxP audits across Celcuity. This role focuses on assessing and mitigating high-risk compliance issues and leading
- [Senior Medical Director](https://www.celcuity.com/jobs/senior-medical-director/) - Position Summary: We are seeking a Senior Medical Director who will report into the Vice President, Clinical Development. You will be responsible for working within Celcuity’s medical team providing medical oversight of service suppliers driving on-going clinical studies and plans and executes the study design protocol development, implementation and monitoring of the company’s new Phase
- [Senior Manager, Clinical Data Management](https://www.celcuity.com/jobs/senior-manager-clinical-data-management/) - Position Summary: We are seeking a Senior Manager, Clinical Data Management who will report into the Executive Director, Clinical Data Management. You will focus on all aspects of the CDM process from project planning, the development of project documentation, system set-up, UAT through database lock. This person is a department-level contributor and may have oversight
- [Senior Manager/Associate Director, Statistical Programming](https://www.celcuity.com/jobs/senior-manager-associate-director-statistical-programming/) - Position Summary: We are seeking a Senior Manager/Associate Director, Statistical Programming, who will report to the Director, Statistical Programming. You will provide technical expertise, and oversight of programming by CRO partners developing all aspects of statistical programming deliverables for the analysis and reporting of clinical study data in accordance with departmental SOPs and regulatory guidelines.
- [Senior or Principal Scientist, Formulation and Process Development](https://www.celcuity.com/jobs/senior-or-principal-scientist-formulation-and-process-development/) - Position Summary: We are seeking a Senior or Principal Scientist, Formulation and Process Development, who will report to the Director, Pharmaceutical Development. You will focus on leading formulation and process development work supporting Celcuity’s drug product development and product lifecycle management. The Sr./Principal Scientist role will join a collaborative Pharmaceutical Development group focused on advancing
- [Senior Manager, Commercial Finance and Accounting](https://www.celcuity.com/jobs/senior-manager-commercial-finance-and-accounting/) - Position Summary: We are seeking a Senior Manager, Commercial Finance and Accounting who will report into the Senior Director, Financial Planning and Analysis. You will lead the finance and accounting functions critical to Celcuity’s commercial operations. This role is responsible for ensuring the accuracy and transparency of our revenue recognition, gross-to-net (GTN) estimates, revenue forecasting
- [QMS Training Manager](https://www.celcuity.com/jobs/qms-training-manager/) - Position Summary: We are seeking a QMS Training Manager who will report to the Director, Quality Management Systems. You will focus on the organization, facilitation, and management of GxP and corporate training curricula at Celcuity. Responsibilities: Manages curricula and learner roles, including periodic review of curricula, learner roles, and training requirements with department heads and
- [Director, Strategic Accounts](https://www.celcuity.com/jobs/director-strategic-accounts/) - POSITION SUMMARY: The regional Director of Strategic Accounts will develop and execute strategies to reduce/remove barriers to access for Celcuity product(s) for assigned strategic oncology accounts. Duties include managing relationships with decision makers at strategic accounts, comprehending their needs, and fostering mutually advantageous solutions through crafting and carrying out business plans for those accounts. This
- [Director, Safety Science](https://www.celcuity.com/jobs/director-safety-science/) - Position Summary: We are seeking a Director, Safety Science who will report into the Vice President, Drug Safety & Pharmacovigilance. You will provide in-depth medical/scientific expertise in the safety evaluation and risk management of Celcuity products in clinical development and/or the post-marketing setting. Responsibilities: Support Safety Physicians with safety-related tasks across commercial products and products
- [Facilities Manager](https://www.celcuity.com/jobs/facilities-manager/) - POSITION SUMMARY: Reporting to the R&D Laboratory Manager, the Facilities Manager will oversee daily operations and maintenance of laboratory, research, and manufacturing environments. This individual will ensure all facility systems operate safely, efficiently, and in compliance with FDA, GMP, and OSHA standards, supporting a high-complexity, regulated laboratory environment. This role will serve as the primary
- [Senior Manager, Accounting](https://www.celcuity.com/jobs/senior-manager-accounting/) - Position Summary: Reporting to the Assistant Controller, the Senior Manager, Accounting, will lead accounting-related functions to ensure the accuracy, transparency, and regulatory compliance of Celcuity’s financial statement close process. The ideal candidate will have extensive experience leading the close process. This position is fully remote for those outside of the Minneapolis area and will be

## News

- [Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-presents-updated-results-of-phase-1b-study-of-gedatolisib-in-combination-with-palbociclib-and-endocrine-therapy-for-er-advanced-breast-cancer-abc-at-the-2021-san-antonio-breast-cancer-symp/) - 78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D) MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today presented a poster
- [Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-to-present-at-the-2021-san-antonio-breast-cancer-symposium/) - MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that an abstract has been accepted for poster presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS), which is being held virtually and in-person
- [Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development](https://www.celcuity.com/news/celcuity-appoints-michael-snitkovsky-as-vp-of-program-management-and-david-bridge-as-vp-of-quality-assurance-and-process-development/) - MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. Michael Snitkovsky joined Celcuity as VP of Program Management and David Bridge joined as
- [Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates](https://www.celcuity.com/news/celcuity-inc-reports-fourth-quarter-and-full-year-2021-financial-results-pivotal-phase-3-trial-design-for-gedatolisib-in-the-treatment-of-advanced-breast-cancer-and-business-updates/) - Finalized pivotal Phase 3 trial design following formal meetings with FDA Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer Presented updated Phase 1b data during a Spotlight Poster-Discussion Session at the 2021 San Antonio Breast Cancer Symposium in December 2021 Entered into a clinical collaboration and supply agreement with Pfizer for
- [Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-fourth-quarter-and-full-year-2021-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it will release its financial results for the fourth quarter and full year 2021 after the stock market close on Wednesday, March 23, 2022.
- [Celcuity to Participate in the Cowen 42nd Annual Health Care Conference](https://www.celcuity.com/news/celcuity-to-participate-in-the-cowen-42nd-annual-health-care-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced its participation in the virtual Cowen 42nd Annual Health Care Conference to be held March 7-9, 2022. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder
- [Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update](https://www.celcuity.com/news/celcuity-receives-fda-fast-track-designation-for-gedatolisib-in-hr-her2-metastatic-breast-cancer-and-provides-corporate-update/) - FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients On track to finalize Phase 3 clinical trial design for gedatolisib with FDA feedback in first quarter Planning to initiate two studies in breast cancer to evaluate gedatolisib in patients selected with
- [Celcuity Inc. Reports First Quarter 2022 Financial Results and Business Updates](https://www.celcuity.com/news/celcuity-inc-reports-first-quarter-2022-financial-results-and-business-updates/) - Entered into $100 Million Private Placement Agreement Finalized pivotal Phase 3 trial design for gedatolisib Received FDA Fast Track designation for gedatolisib in HR+/HER2- advanced breast cancer Management to host webcast and conference call today, May 16, 2022, at 4:30 p.m. ET MINNEAPOLIS, MN / ACCESSWIRE / May 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a
- [Celcuity Inc. Schedules Release of First Quarter 2022 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-first-quarter-2022-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN / ACCESSWIRE / May 9, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it will release its financial results for the first quarter 2022 after the stock market close on Monday, May 16, 2022. Management will host
- [Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences](https://www.celcuity.com/news/celcuity-to-participate-in-upcoming-needham-and-canaccord-genuity-investor-conferences/) - MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following virtual investor conferences: A company presentation at the 21st Annual
- [Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-second-quarter-2022-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN / ACCESSWIRE / August 4, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that it will release its financial results for the second quarter 2022 after the stock market close on Thursday, August 11, 2022. Management will host a webcast/teleconference the
- [Celcuity to Participate in the Canaccord Genuity 42nd Annual Growth Conference](https://www.celcuity.com/news/celcuity-to-participate-in-the-canaccord-genuity-42nd-annual-growth-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / August 3, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced its participation in the Canaccord Genuity 42nd Annual Growth Conference to be held in Boston on August 8-11, 2022. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity,
- [Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer](https://www.celcuity.com/news/celcuity-announces-fda-breakthrough-therapy-designation-for-gedatolisib-for-treatment-of-hr-her2-metastatic-breast-cancer/) - MINNEAPOLIS, MN / ACCESSWIRE / July 18, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted gedatolisib Breakthrough Therapy designation for the treatment of patients with HR+/HER2- metastatic breast cancer whose disease progressed during
- [Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences](https://www.celcuity.com/news/celcuity-to-participate-in-upcoming-craig-hallum-and-jefferies-investor-conferences-2/) - MINNEAPOLIS, MN / ACCESSWIRE / May 26, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences: One-on-one and small group meetings at the
- [Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-to-present-additional-data-for-gedatolisib-at-the-2022-san-antonio-breast-cancer-symposium/) - MINNEAPOLIS, MN / ACCESSWIRE / November 22, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2022 San Antonio
- [Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference](https://www.celcuity.com/news/celcuity-to-participate-in-the-13th-annual-craig-hallum-alpha-select-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / November 10, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one and small group meetings at the 13th Annual Craig-Hallum Alpha Select
- [Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-third-quarter-2022-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN/ ACCESSWIRE / November 3, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that it will release its financial results for the third quarter 2022 after the stock market close on Thursday, November 10, 2022. Management will host a webcast/teleconference
- [Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors](https://www.celcuity.com/news/celcuity-appoints-polly-murphy-d-v-m-ph-d-to-board-of-directors/) - Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of Directors MINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D.
- [Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-second-quarter-2022-financial-results-and-provides-corporate-update/) - Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancer Entered into agreements for the private placement sale of $100 million of equity and to increase available debt facility from $25 million to $75 million The Phase 3 VICTORIA-1 clinical trial remains on track to dose the first patient in the
- [Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023](https://www.celcuity.com/news/celcuity-to-present-preclinical-data-on-therapeutic-effects-of-gedatolisib-in-gynecological-cancer-models-at-aacr-annual-meeting-2023/) - MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the
- [Celcuity to Participate in Cowen's 43rd Annual Health Care Conference](https://www.celcuity.com/news/celcuity-to-participate-in-cowens-43rd-annual-health-care-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen's 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023. Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, is scheduled to
- [Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium](https://www.celcuity.com/news/celcuity-presents-preclinical-data-on-therapeutic-effects-of-gedatolisib-in-prostate-cancer-at-asco-gu-cancers-symposium/) - Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other
- [Celcuity Closes $100 Million Private Placement](https://www.celcuity.com/news/celcuity-closes-100-million-private-placement/) - MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses. The closing follows dosage of the first patient in Celcuity's Phase 3 clinical trial, VIKTORIA-1, evaluating
- [Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-presents-updated-results-of-phase-1b-study-of-gedatolisib-in-patients-with-advanced-breast-cancer-at-the-2022-san-antonio-breast-cancer-symposium/) - High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation status Median progression free survival (PFS) of 42.3 months was reported for patients who were treatment naïve in the advanced setting MINNEAPOLIS, MN / ACCESSWIRE / December 9, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company
- [Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer](https://www.celcuity.com/news/celcuity-announces-first-patient-dosed-in-phase-3-viktoria-1-clinical-trial-of-gedatolisib-for-the-treatment-of-hr-her2-advanced-breast-cancer/) - First patient dosing enables closing of $100 million PIPE financing and drawdown of $20 million term loan tranche MINNEAPOLIS, MN / ACCESSWIRE / December 7, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 3 clinical trial, VIKTORIA-1, evaluating
- [Celcuity Inc. Schedules Release of First Quarter 2023 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-first-quarter-2023-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN / ACCESSWIRE / May 8, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2023 after the stock market close on Monday, May 15, 2023. Management will host a webcast/teleconference the same day
- [Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023](https://www.celcuity.com/news/celcuity-presents-preclinical-data-on-therapeutic-effects-of-gedatolisib-in-gynecological-cancer-models-at-aacr-annual-meeting-2023/) - Gedatolisib demonstrated superior anti-proliferative potency and efficacy in endometrial, ovarian and cervical cancer cell lines compared to other PAM inhibitors evaluated regardless of PTEN, P13K, or AKT mutational status MINNEAPOLIS, MN / ACCESSWIRE / April 18, 2023 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from
- [Celcuity to Participate in 22nd Annual Needham Virtual Healthcare Conference](https://www.celcuity.com/news/celcuity-to-participate-in-22nd-annual-needham-virtual-healthcare-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / April 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled to present at 1:30 p.m. ET on Wednesday, April
- [Celcuity Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update/) - Dosing of first patient in VIKTORIA-1 in the fourth quarter triggered closing of $100 million PIPE financing and drawdown of $20 million term loan tranche, which extends cash runway through 2025 Updated clinical data from the Phase 1b advanced breast cancer trial with gedatolisib was presented at SABCS in December - median PFS was 42.3
- [Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-fourth-quarter-and-full-year-2022-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market close on Thursday, March 23, 2023. Management will host a webcast/teleconference
- [Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-second-quarter-2023-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2023 after the stock market close on Thursday, August 10, 2023. Management will host a webcast/teleconference the same day
- [Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023](https://www.celcuity.com/news/celcuity-to-participate-in-the-btig-virtual-biotechnology-conference-2023/) - MINNEAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held on August 7-8, 2023. About Celcuity
- [Celcuity Set to Join Russell 2000 and 3000 Indexes](https://www.celcuity.com/news/celcuity-set-to-join-russell-2000-and-3000-indexes/) - MINNEAPOLIS, MN / ACCESSWIRE / June 20, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, is set to join the Russell 2000® and 3000® Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, according to the most recent
- [Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences](https://www.celcuity.com/news/celcuity-to-participate-in-upcoming-craig-hallum-and-jefferies-investor-conferences/) - MINNEAPOLIS, MN / ACCESSWIRE / May 24, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in the following investor conferences: One-on-one and small group meetings at the 20th Annual Craig-Hallum Institutional Investor
- [Celcuity Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Updates](https://www.celcuity.com/news/celcuity-inc-reports-first-quarter-2023-financial-results-and-provides-corporate-updates/) - Presented updated results for treatment-naïve patients from Phase 1b study of gedatolisib at the ESMO Breast Cancer Annual Congress - median progression free survival (PFS) was 48.6 months Presented nonclinical prostate cancer data at ASCO GU Cancers Symposium demonstrating the superior therapeutic effect of gedatolisib compared to other PI3K, AKT, and mTOR inhibitors regardless of
- [Celcuity Presents Updated Results from Phase 1b Study of Gedatolisib in Treatment-Naïve Patients at the 2023 ESMO Breast Cancer Annual Congress](https://www.celcuity.com/news/celcuity-presents-updated-results-from-phase-1b-study-of-gedatolisib-in-treatment-naive-patients-at-the-2023-esmo-breast-cancer-annual-congress/) - Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were treated with gedatolisib in combination with palbociclib and letrozole Median duration of response (DOR) was 46.9 months MINNEAPOLIS, MN / ACCESSWIRE / May 12, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of
- [Celcuity Inc. Announces $50 Million Private Placement](https://www.celcuity.com/news/celcuity-inc-announces-50-million-private-placement/) - MINNEAPOLIS, MN / ACCESSWIRE / October 18, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, announced today that it has entered into a securities purchase agreement to sell securities in a private placement that is expected to result in gross proceeds of approximately $50 million. In the private
- [Celcuity to Host Virtual Science Day for Investors](https://www.celcuity.com/news/celcuity-to-host-virtual-science-day-for-investors/) - Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor types Discussion of the planned Phase 1b/2 trial for gedatolisib in combination with Nubeqa ® (darolutamide) in patients with mCRPC Event to be webcast from 10:00 a.m. – 12:00 p.m. ET
- [Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial](https://www.celcuity.com/news/celcuity-enters-into-a-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-provide-nubeqa-darolutamide-for-planned-phase-1b-2-clinical-trial/) - MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity’s Phase 1b/2 clinical trial of gedatolisib and Nubeqa® (darolutamide) in patients with metastatic castration resistant
- [Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates](https://www.celcuity.com/news/celcuity-inc-reports-second-quarter-2023-financial-results-and-provides-corporate-updates/) - Phase 3 VIKTORIA-1 clinical trial is now recruiting patients at nearly 200 sites in 20 countries Presented updated results from Phase 1b study of gedatolisib in treatment-naïve advanced breast cancer at the ESMO Breast Cancer Annual Congress Median progression free survival (PFS) was 48.6 months in treatment-naïve patients with HR+/HER2- advanced breast cancer who were
- [Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference](https://www.celcuity.com/news/celcuity-to-participate-in-the-6th-annual-evercore-isi-healthconx-conference/) - MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6 th Annual Evercore ISI HealthCONx Conference held in Miami. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 12:30 p.m.
- [Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates](https://www.celcuity.com/news/celcuity-inc-reports-third-quarter-2023-financial-results-and-provides-corporate-updates/) - Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a clinical trial collaboration and supply agreement with Bayer AG to provide Nubeqa ® (darolutamide) for planned Phase 1b/2 clinical trial Raised $50 million in private placement sale of equity Management to
- [Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-third-quarter-2023-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2023 before the market opens on Monday, November 13, 2023. Management will host a webcast/teleconference the same day at 8:00
- [Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-stifel-and-jefferies-investor-conferences/) - MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A formal presentation at the Stifel
- [Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer](https://www.celcuity.com/news/celcuity-announces-first-patient-dosed-in-phase-1b-2-celc-g-201-clinical-trial-of-gedatolisib-for-the-treatment-of-metastatic-castration-resistant-prostate-cancer/) - MINNEAPOLIS, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company developing targeted therapies for oncology, today announced that the first patient has been dosed in its Phase 1b/2 study (CELC-G-201) evaluating gedatolisib in combination with Nubeqa ® (darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with metastatic castration resistant
- [Celcuity Appoints Eldon Mayer as Chief Commercial Officer](https://www.celcuity.com/news/celcuity-appoints-eldon-mayer-as-chief-commercial-officer/) - MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical
- [Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-presents-preclinical-data-on-therapeutic-effects-of-gedatolisib-in-breast-cancer-models-at-the-2023-san-antonio-breast-cancer-symposium/) - MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR (PAM) inhibitors in breast cancer cell lines during a poster session at the 2023 San Antonio Breast Cancer Symposium (SABCS). The preclinical
- [Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-to-present-preclinical-data-for-gedatolisib-at-the-2023-san-antonio-breast-cancer-symposium/) - MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract accepted for a poster presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website. The 2023 San Antonio Breast Cancer Symposium
- [Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-update/) - Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mTOR inhibitors at the 2023 SABCS Raised $65 million from the sale of equity; expect cash, cash equivalents,
- [Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-fourth-quarter-and-full-year-2023-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same
- [Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024](https://www.celcuity.com/news/celcuity-to-participate-in-leerink-partners-global-biopharma-conference-2024/) - MINNEAPOLIS, March 06, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 to be held in Miami on March 11-13, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for
- [Celcuity to Participate in Cowen's 44th Annual Health Care Conference](https://www.celcuity.com/news/celcuity-to-participate-in-cowens-44th-annual-health-care-conference/) - MINNEAPOLIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in Cowen’s 44 th Annual Health Care Conference to be held in Boston on March 4-6, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside
- [Celcuity Announces Pricing of Underwritten Common Stock Offering](https://www.celcuity.com/news/celcuity-announces-pricing-of-underwritten-common-stock-offering/) - MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of an underwritten offering of 3,871,000 shares of its common stock at an offering price of $15.50 per share. All of the securities are to be sold by Celcuity.
- [Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-first-quarter-financial-results-and-provides-corporate-update/) - The Phase 3 VIKTORIA-1 trial remains on track to report topline data from PIK3CA wild type patient sub-group in the second half of 2024 First patient dosed in a Phase 1b/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer $177.7 million in cash, cash equivalents and short-term
- [Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-first-quarter-2024-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30
- [Celcuity To Present at Upcoming Needham and Stifel Investor Conferences](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences-2/) - MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the 23 rd Annual Needham
- [Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing](https://www.celcuity.com/news/celcuity-inc-announces-plan-to-initiate-a-phase-3-clinical-trial-for-gedatolisib-as-first-line-treatment-for-hr-her2-advanced-breast-cancer-and-secures-approximately-62-million-debt-financing/) - The Phase 3 clinical trial will evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer who are endocrine therapy resistant Received an additional term loan of approximately $62 million in conjunction with an amendment to an existing debt facility agreement MINNEAPOLIS, May 30, 2024 (GLOBE NEWSWIRE)
- [Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-third-quarter-2024-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2024 after the market closes on Thursday, November 14, 2024. Management will host a webcast/teleconference the same day at 4:30
- [Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-second-quarter-financial-results-and-provides-corporate-update/) - Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2025 Expect to reach enrollment target for VIKTORIA-1 PIK3CA WT cohort in Q4 2024 and report topline data for this
- [Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-second-quarter-2024-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/teleconference the same day at 4:30
- [Celcuity To Participate in Jefferies Global Healthcare Conference](https://www.celcuity.com/news/celcuity-to-participate-in-jefferies-global-healthcare-conference/) - MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Jefferies Global Healthcare Conference to be held in New York on June 4-6, 2024. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a
- [Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-fourth-quarter-and-full-year-2024-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Monday, March 31, 2025. Management will host a webcast/teleconference the same
- [Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences](https://www.celcuity.com/news/celcuity-to-participate-at-upcoming-cowen-and-leerink-investor-conferences/) - MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen
- [Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-presents-overall-survival-data-from-phase-1b-study-evaluating-gedatolisib-in-combination-with-palbociclib-and-endocrine-therapy-at-the-2024-san-antonio-breast-cancer-symposium/) - Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with a CDK4/6 inhibitor was 33.9 months MINNEAPOLIS, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies
- [Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-third-quarter-financial-results-and-provides-corporate-update/) - The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025 Approximately $264 million in cash, cash equivalents and investments at end of Q3 2024 expected to fund current clinical development program activities through 2026 Management to host
- [Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences](https://www.celcuity.com/news/celcuity-inc-to-present-at-upcoming-stifel-and-jefferies-investor-conferences/) - MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2024
- [Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-first-quarter-2025-financial-results-and-provides-corporate-update/) - The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in
- [Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-first-quarter-2025-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30
- [Celcuity To Present at Upcoming Needham and Stifel Investor Conferences](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-needham-and-stifel-investor-conferences/) - MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2025
- [Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-corporate-update/) - The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025 VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025 Presented encouraging preliminary overall survival data from the Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy at
- [Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042](https://www.celcuity.com/news/celcuity-announces-issuance-of-new-patent-for-gedatolisib-that-extends-patent-exclusivity-into-2042/) - MINNEAPOLIS, July 14, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the issuance of U.S. Patent No. 12,350,276 covering the clinical dosing regimen for its lead drug candidate, gedatolisib, in ER+/HER2- breast cancer patients. The patent extends Celcuity’s patent exclusivity in the
- [Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib](https://www.celcuity.com/news/celcuity-reports-clinical-data-from-two-early-phase-studies-of-gedatolisib/) - • In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer (“mCRPC”),the six-month radiographic progression free survival (“rPFS”) rate was 66% • In a Phase 2 clinical trial of gedatolisib plus trastuzumab-pkrb as 3L+ therapyin patients with HER2+ metastatic breast cancer (“mBC”),the objective response
- [Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-td-cowen-and-jefferies-investor-conferences/) - MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen:
- [Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer](https://www.celcuity.com/news/celcuity-announces-first-patient-dosed-in-phase-3-viktoria-2-clinical-trial-of-gedatolisib-as-a-first-line-treatment-for-hr-her2-advanced-breast-cancer/) - MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the first patient has been dosed in VIKTORIA-2, its Phase 3 clinical trial evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast
- [Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants](https://www.celcuity.com/news/celcuity-inc-announces-pricing-of-concurrent-public-offerings-of-2-750-convertible-senior-notes-due-2031-and-common-stock-and-pre-funded-warrants/) - MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public offering of $175,000,000 aggregate principal amount of its 2.750% convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes
- [Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock](https://www.celcuity.com/news/celcuity-inc-announces-concurrent-public-offerings-of-convertible-senior-notes-due-2031-and-common-stock/) - MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public offerings of $150,000,000 aggregate principal amount of its convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $75,000,000 of
- [Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer](https://www.celcuity.com/news/celcuity-to-announce-topline-results-for-the-pik3ca-wild-type-cohort-from-phase-3-viktoria-1-trial-in-hr-her2-advanced-breast-cancer/) - MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the Phase 3 VIKTORIA-1
- [Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial](https://www.celcuity.com/news/celcuity-announces-clinically-meaningful-improvement-in-both-progression-free-survival-pfs-primary-endpoints-from-pik3ca-wild-type-cohort-of-phase-3-viktoria-1-trial/) - Hazard Ratios and Improvements in Median PFS areUnprecedented in HR+/HER2- Advanced Breast Cancer (“ABC”) Gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) reduced the risk of disease progression or death by 76% vs. fulvestrant (HR=0.24; 95% CI: 0.17–0.35; p
- [Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance](https://www.celcuity.com/news/celcuity-announces-upsized-senior-secured-term-loan-facility-of-500-million-with-innovatus-capital-partners-and-oxford-finance/) - MINNEAPOLIS, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (“Celcuity”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into an amendment to its existing senior secured credit facility with an affiliate of Innovatus Capital Partners, LLC (“Innovatus”) and Oxford Finance LLC, and its affiliates (together, “Oxford”).
- [Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program](https://www.celcuity.com/news/celcuity-to-initiate-nda-submission-of-gedatolisib-in-pik3ca-wild-type-cohort-in-hr-her2-advanced-breast-cancer-under-fdas-real-time-oncology-review-program/) - MINNEAPOLIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S. Food and Drug Administration (“FDA”) agreed to accept its New Drug Application (“NDA”) for gedatolisib in HR+/HER2- advanced breast cancer (“ABC”) for review under the Real-Time Oncology Review (“RTOR”)
- [Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-second-quarter-2025-financial-results-and-provides-corporate-update/) - Reported statistically significant and clinically meaningful improvement in both primary endpoints from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial Hazard ratios and improvements in median progression-free survival (“PFS”) are unprecedented in HR+/HER2- advanced breast cancer (“ABC”) Expect to submit a New Drug Application (“NDA”) for gedatolisib, based on data from the PIK3CA
- [Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-second-quarter-2025-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30
- [Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-stifel-2025-healthcare-conference/) - MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025. Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a
- [Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC")](https://www.celcuity.com/news/celcuity-presents-updated-data-at-the-2025-esmo-congress-from-phase-1-study-evaluating-gedatolisib-plus-darolutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc/) - Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical results
- [Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress](https://www.celcuity.com/news/celcuity-to-present-results-from-the-pivotal-phase-3-viktoria-1-trial-at-the-2025-european-society-for-medical-oncology-esmo-congress/) - MINNEAPOLIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that a late breaking abstract reporting clinical data from the Phase 3 VIKTORIA-1 trial has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress,
- [Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer](https://www.celcuity.com/news/detailed-results-from-pik3ca-wild-type-cohort-of-phase-3-viktoria-1-trial-presented-at-2025-esmo-congress-demonstrate-potential-for-gedatolisib-regimens-to-be-practice-changing-for-patients-with-hr-h/) - Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with gedatolisib + fulvestrant (“gedatolisib doublet”) Study treatment discontinuation due to treatment related adverse events was reported in 2.3% of patients
- [Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial](https://www.celcuity.com/news/celcuity-provides-update-on-status-of-the-pik3ca-mutated-cohort-of-phase-3-viktoria-1-trial-and-releases-additional-data-analysis-from-phase-1b-clinical-trial/) - PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) of 14.6 months in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer (“ABC”) MINNEAPOLIS, Oct. 18, 2025
- [Celcuity to Present Updated Data from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-to-present-updated-data-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium/) - MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an abstract was accepted for an oral presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS) and is now available on the SABCS website. The 2025 SABCS is being held virtually and in-person
- [Celcuity To Present at Upcoming 8th Annual Evercore Healthcare Conference](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-8th-annual-evercore-healthcare-conference/) - MINNEAPOLIS, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 8th Annual Evercore Healthcare Conference to be held in Miami, Florida on December 2-4, 2025. Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, is scheduled for a fireside chat at 7:30 a.m. ET on Wednesday, December 3, 2025. A
- [Celcuity Announces Completion of Submission of Its New Drug Application to the U.S. FDA for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer](https://www.celcuity.com/news/celcuity-announces-completion-of-submission-of-its-new-drug-application-to-the-u-s-fda-for-gedatolisib-in-hr-her2-pik3ca-wild-type-advanced-breast-cancer/) - MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the completion of the submission of its New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), advanced breast cancer
- [Celcuity Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-third-quarter-2025-financial-results-and-provides-corporate-update/) - Presented detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Medical Oncology (“ESMO”) Congress Presented updated clinical results from the Phase 1b portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide)
- [Celcuity Inc. Schedules Release of Third Quarter 2025 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-third-quarter-2025-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, November 12, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results
- [Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase 3 VIKTORIA-1 Trial at the 2025 San Antonio Breast Cancer Symposium](https://www.celcuity.com/news/celcuity-presents-updated-results-from-the-pik3ca-wild-type-cohort-of-the-phase-3-viktoria-1-trial-at-the-2025-san-antonio-breast-cancer-symposium/) - For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival (“PFS”) was 12.4 months with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and 10.0 months with gedatolisib + fulvestrant (“gedatolisib doublet”) versus 1.9 months for fulvestrant For patients enrolled in the U.S., Canada, Western Europe, and Asia Pacific, median PFS was 16.6
- [Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer](https://www.celcuity.com/news/celcuity-announces-fda-acceptance-of-new-drug-application-for-gedatolisib-in-hr-her2-pik3ca-wild-type-advanced-breast-cancer/) - FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026 MINNEAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for filing its New Drug Application (“NDA”)
- [Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026](https://www.celcuity.com/news/celcuity-to-present-at-upcoming-guggenheim-emerging-outlook-biotech-summit-2026/) - MINNEAPOLIS, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 to be held in New York, New York on February 11-12, 2026. Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity,
- [Celcuity Appoints Charles Romp to its Board of Directors](https://www.celcuity.com/news/celcuity-appoints-charles-romp-to-its-board-of-directors/) - MINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Charles (Chip) R. Romp to its Board of Directors. Mr. Romp brings over 25 years of experience in the pharmaceutical industry to Celcuity, including leadership of sales teams
- [Celcuity To Participate in Upcoming Investor Conferences](https://www.celcuity.com/news/celcuity-to-participate-in-upcoming-investor-conferences/) - MINNEAPOLIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen
- [Celcuity Announces Publication of Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Study of Gedatolisib Regimens in HR+/HER2- Advanced Breast Cancer in Journal of Clinical Oncology](https://www.celcuity.com/news/celcuity-announces-publication-of-results-from-pik3ca-wild-type-cohort-of-phase-3-viktoria-1-study-of-gedatolisib-regimens-in-hr-her2-advanced-breast-cancer-in-journal-of-clinical-oncology/) - As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus fulvestrant by 76% and 67%, respectively MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced
- [Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial](https://www.celcuity.com/news/celcuity-announces-clinical-trial-collaboration-and-supply-agreement-with-pfizer-to-provide-ibrancer-palbociclib-for-planned-phase-3-clinical-trial/) - MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to provide Ibrance® (palbociclib) for use in Celcuity's Phase 3 clinical
- [Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences](https://www.celcuity.com/news/celcuity-to-participate-in-upcoming-jefferies-and-craig-hallum-investor-conferences/) - MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in virtual meetings with investors at the following conferences: 12th Annual Craig-Hallum
- [Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-third-quarter-2021-financial-results-and-provides-corporate-update/) - On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the 2021 San Antonio Breast Cancer Symposium in December 2021 Entered into clinical trial collaboration with University of Rochester Wilmot Cancer Center
- [Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-third-quarter-2021-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the third quarter 2021 after the stock market close on Monday, November 8, 2021. Management will host
- [Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases](https://www.celcuity.com/news/celcuity-announces-clinical-trial-collaboration-with-university-of-rochester-wilmot-cancer-center-and-puma-to-study-patients-with-breast-cancer-brain-metastases/) - Study will evaluate the efficacy and safety of NERLYNX® plus XELODA® in patients selected by the CELsignia® Test who have metastatic HER2-negative breast cancer with brain metastases The unique tumor insights CELsignia generates enable identification of new potential applications for targeted therapies and development of potential first-in-class drugs Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
- [Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference](https://www.celcuity.com/news/celcuity-to-participate-in-the-canaccord-genuity-41st-annual-growth-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the Canaccord Genuity 41st Annual Growth Conference to be held August 10-12, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity,
- [Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-second-quarter-2021-financial-results-and-provides-corporate-update/) - Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities After follow-on offering, Celcuity had approximately $94.4 million of cash on hand Expanded clinical development and clinical operations capabilities with appointment of two new senior executives and the addition of
- [Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast](https://www.celcuity.com/news/celcuity-inc-schedules-release-of-second-quarter-2021-financial-results-and-webcast/) - MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for treating patients with cancer, today announced that it will release its financial results for the second quarter 2021 after the stock market close on Monday, August 9, 2021. Management will host
- [Celcuity to Participate in the William Blair Biotech Focus Conference](https://www.celcuity.com/news/celcuity-to-participate-in-the-william-blair-biotech-focus-conference/) - MINNEAPOLIS, MN / ACCESSWIRE / July 8, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced its participation in the William Blair Biotech Focus Conference to be held July 14-15, 2021. Brian Sullivan, Chairman, Chief Executive Officer, and Co-Founder of Celcuity,
- [Celcuity Announces Pricing of Follow-on Offering](https://www.celcuity.com/news/celcuity-announces-pricing-of-follow-on-offering/) - MINNEAPOLIS, MN / ACCESSWIRE / June 28, 2021 /Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $25.00 per share. As part
- [Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations](https://www.celcuity.com/news/celcuity-announces-appointment-of-dr-igor-gorbatchevsky-as-vp-of-clinical-development-and-jill-krause-as-vp-of-clinical-operations/) - MINNEAPOLIS, MN / ACCESSWIRE / June 9, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating patients with cancer, today announced the addition of two new senior executives to its clinical drug development and operations team. Igor Gorbatchevsky, MD, joined Celcuity as VP of Clinical Development
- [Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-first-quarter-2021-financial-results-and-provides-corporate-update/) - Entered into worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K/mTOR inhibitor, in clinical development for breast cancer Announced encouraging preliminary data from a Phase 1b trial of gedatolisib plus Ibrance® and endocrine therapy for patients with ER+/HER2- metastatic breast cancer, in which gedatolisib showed a potentially differentiated safety and tolerability
- [Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call](https://www.celcuity.com/news/celcuity-schedules-release-of-fourth-quarter-and-full-year-2025-financial-results-and-webcast-conference-call/) - MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same
- [Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://www.celcuity.com/news/celcuity-inc-reports-release-of-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update/) - The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription Drug User Fee Act (“PDUFA”) goal date of July 17, 2026, for gedatolisib in HR+/HER2-/PIK3CA wild-type (“WT”) advanced breast cancer (“ABC”) Results from PIK3CA WT cohort of Phase 3 VIKTORIA-1 study of gedatolisib regimens in

## Team Members

- [Sunni Miller](https://www.celcuity.com/team/sunni-miller/) - Sunni has over 20 years of experience in the pharmaceutical industry, building and directing regulatory teams and managing various therapeutic development programs and health authority submissions and interactions through all stages of development. Before joining Celcuity, Sunni served as vice president (VP) of regulatory affairs and clinical quality assurance at Gossamer Bio and as senior
- [Nadene Zack](https://www.celcuity.com/team/nadene-zack/) - Nadene has over 20 years of experience working in clinical operations for clinical-stage pharmaceutical and biotechnology companies. She has broad experience in therapeutic areas (oncology, psychiatry, rheumatology and pain, pulmonology, infectious disease, and women’s health). Before joining Celcuity, Nadene held positions of increasing responsibility at Pfizer, Cypress Bioscience, Aragon Pharmaceuticals, and Daré Bioscience, leading to
- [Bernhard Lampert, PhD](https://www.celcuity.com/team/bernhard-lampert-phd/) - Bernhard has over 30 years of drug development experience in the pharmaceutical and biotech industries, including 10 years in large, fully integrated pharmaceutical companies, including Gilead and GSK. He received his PhD in medicinal chemistry from the University of Georgia. Bernhard has authored/co-authored publications in peer-reviewed journals and is the co-inventor on patents on the
- [David Bridge](https://www.celcuity.com/team/david-bridge/) - David has over 30 years of experience as a quality assurance leader, including quality oversight responsibilities for laboratory, manufacturing, and clinical functions. Prior to joining Celcuity, David was director of quality assurance at the Duke University Clinical Research Institute, one of the world’s largest academic clinical research organizations. He had previously served as senior director,
- [Fred Kerwood](https://www.celcuity.com/team/fred-kerwood/) - Fred has over 30 years of program management and clinical operations experience in the pharmaceutical industry. Before joining Celcuity, Fred was vice president (VP) of clinical operations at CytomX Therapeutics, where he oversaw the execution of their oncology programs, including a Phase II program in breast cancer. Prior to CytomX, Fred was with the immuno-oncology
- [Igor Gorbatchevsky, MD](https://www.celcuity.com/team/igor-gorbatchevsky-md/) - Igor has over two decades of hands-on oncology drug development experience, including successful regulatory IND and NDA/BLA filings across several drug classes. Prior to joining Celcuity, Igor worked for MEI Pharma, an oncology-focused biopharmaceutical company, where he was the vice president (VP) of clinical development. MEI’s pipeline included zandelisib, an oral PI3K-delta inhibitor. He had
- [Eldon Mayer](https://www.celcuity.com/team/eldon-mayer/) - Eldon has over 30 years of biopharma commercial experience in companies ranging from early stage biotechs to full-scale pharmaceutical companies across many therapeutic areas, including oncology. Prior to joining Celcuity, Eldon was chief commercial officer at Eiger Biopharmaceuticals, where he led the commercial planning and execution of several pipeline assets including the global launch of
- [Brent Eilefson, JD](https://www.celcuity.com/team/brent-eilefson/) - Brent has over 29 years of legal experience, including 20 years in the pharmaceutical industry. Prior to joining Celcuity, Brent was vice president, legal affairs, chief compliance officer, and secretary at Upsher-Smith Laboratories, where he held positions of increasing responsibility within management including leading the legal, compliance, and corporate secretarial functions. As a member of
- [Vicky Hahne](https://www.celcuity.com/team/vicky-hahne/) - Vicky has more than 20 years of financial leadership experience, including the past 10 years in the healthcare industry. Prior to joining Celcuity, Vicky served as controller of Respiratory Technologies Inc., a medical device manufacturer. While at Respiratory Technologies, she played a key role in the due diligence process to sell the company to Koninklijke
- [Lance Laing, PhD](https://www.celcuity.com/team/lance-laing-phd/) - Lance’s career spans more than 30 years in drug discovery research and technology development. He received his doctorate in biophysics and biochemistry from Johns Hopkins University and completed a National Institutes of Health postdoctoral fellowship at Washington University Medical School. He has received multiple U.S. and international patents. His drug discovery research has led him
- [Brian Sullivan](https://www.celcuity.com/team/brian-sullivan/) - Brian has over 25 years of experience founding and building successful technology companies. He was chairman and CEO of Sterilmed, a medical device company, from 2003 until its sale to Johnson & Johnson for $330 million in 2011. Previously he was co-founder and CEO of Recovery Engineering, a filtration company that he took public and
- [Charles (Chip) R. Romp](https://www.celcuity.com/team/charles-chip-r-romp/) - Chip has served as a member of Celcuity’s board of directors since February 2026. Mr. Romp has over 25 years of experience building the pharmaceutical commercialization process from development stage to successful global product. Mr. Romp is currently Chief Executive Officer at Secura Bio. Previously, he was Executive Vice President, US Commercial for Seagen, Inc.,
- [Adam Brufsky, MD, PhD](https://www.celcuity.com/team/adam-brufsky-md-phd/) - Dr. Brufsky is professor of medicine at the University of Pittsburgh School of Medicine and serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women’s Cancer Program, part of the UPMC Hillman Cancer Center,
- [Lee S. Schwartzberg, MD, FACP](https://www.celcuity.com/team/lee-s-schwartzberg-md-facp/) - Dr. Schwartzberg is the executive director of West Cancer Center and founding member of West Clinic, a multispecialty oncology practice affiliated with the University of Tennessee. He also serves as professor of medicine and division chief of hematology/oncology at the University of Tennessee Health Science Center. His major research interests include new therapeutic approaches to
- [Mothaffar F. Rimawi, MD](https://www.celcuity.com/team/mothaffar-f-rimawi-md/) - Dr. Rimawi is an associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine. He also serves as the executive medical director and co-leader of the Breast Cancer Program at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine. His research is
- [Mark Pegram, MD, PhD](https://www.celcuity.com/team/mark-pegram-md-phd/) - Dr. Pegram is the first director of the Breast Cancer Oncology Program at Stanford Women’s Cancer Center, and the co-director of Stanford’s Molecular Therapeutics Program. Dr. Pegram’s commitment to translational science includes having played a major role in developing the drug Herceptin® as a treatment for HER2-positive breast cancer. His laboratory experiments demonstrated that combining
- [Ben Ho Park, MD, PhD](https://www.celcuity.com/team/ben-ho-park-md-phd/) - Dr. Park, an internationally renowned breast cancer expert, was recently appointed as the co-leader of the Breast Cancer Research Program, associate director for translational research and director of precision oncology at Vanderbilt-Ingram Cancer Center. Dr. Park is from Saginaw, MI, and received his bachelor’s degree from the University of Chicago and then completed a dual
- [Alberto Montero, MD, MBA, CPHQ](https://www.celcuity.com/team/alberto-montero-md-mba-cphq/) - Dr. Montero is clinical director of the Breast Cancer Medical Oncology Program at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University School of Medicine. He has experience designing and performing cost-effective decision analyses in the oncology field. Dr. Montero has over a decade of experience in all
- [Ron McGlennen, MD](https://www.celcuity.com/team/ron-mcglennen-md/) - Dr. McGlennen is president and medical director of Access Genetics, a molecular diagnostics company he cofounded in 2001. Previously, he was an associate professor at the University of Minnesota. He also serves as Celcuity’s laboratory medical director.
- [Stanley Marks, MD](https://www.celcuity.com/team/stanley-marks-md/) - Dr. Marks is chairman of the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center and serves as chief of the division of hematology/oncology at UPMC Shadyside. Dr. Marks also is the medical director of Forbes Hospice and clinical associate professor of medicine at the University of Pittsburgh School of Medicine. Dr. Marks served as
- [Bora Lim, MD](https://www.celcuity.com/team/bora-lim-md/) - Dr. Lim is an assistant professor of breast medical oncology in the Section of Translational Breast Cancer Research at the University of Texas MD Anderson Cancer Center. She is a translational investigator researching novel therapeutic strategies to halt or treat aggressive breast cancer by apoptosis (effective cancer cell killing) induction. She studies new ways of
- [Carol Lange, PhD](https://www.celcuity.com/team/carol-lange-phd/) - Dr. Lange is professor of medicine and pharmacology at the University of Minnesota. She is also Endowed Chair of the Tickle Family Land Grant in Breast Cancer Research and director of the Women’s Cancer Program at the University of Minnesota. Dr. Lange studies the molecular biology of breast cancer. Her laboratory is focused on the
- [Hung Khong, MD](https://www.celcuity.com/team/hung-khong-md/) - Dr. Khong is an associate professor, medical oncology at the University of South Florida College of Medicine Moffitt Cancer Center. He specializes in the treatment of breast cancer of all stages. He is interested in combining treatment methods such as chemotherapy or radiotherapy with immunotherapy and chemotherapy with targeted therapy. Dr. Khong has developed several
- [John Katzenellenbogen, PhD](https://www.celcuity.com/team/john-katzenellenbogen-phd/) - Dr. Katzenellenbogen is research professor of chemistry at the University of Illinois, an affiliate of the Beckman Institute and Department of Bioengineering, and a fellow of the American Academy of Arts and Sciences. His research has focused on aspects of the structure, function, and the use of steroid receptors, and includes biochemical and biophysical studies
- [Benita Katzenellenbogen, PhD](https://www.celcuity.com/team/benita-katzenellenbogen-phd/) - Dr. Katzenellenbogen is the Swanlund Professor of Molecular and Integrative Physiology and the Swanlund Professor of Cell and Developmental Biology at the University of Illinois School of Molecular and Cellular Biology. Her research interests include regulation of gene expression, signal transduction, and cell proliferation and phenotypic properties by hormones and growth factors, as well as
- [Sara Hurvitz, MD](https://www.celcuity.com/team/sara-hurvitz-md/) - Dr. Hurvitz is director, Breast Cancer Clinical Research Programs at the Geffen School of Medicine at UCLA and an assistant professor of medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA. She is also the co-director of the Santa Monica-UCLA Outpatient Hematology/Oncology Practice and medical director of the Jonsson Comprehensive Cancer Center Clinical
- [Edward Greeno, MD](https://www.celcuity.com/team/edward-greeno-md/) - Dr. Greeno is medical director of the Hematology/Oncology Clinic at the University of Minnesota and an associate professor at the University of Minnesota Medical School. He has been listed as one of the Best Doctors in America for a number of years.
- [Manfred Auer, PhD](https://www.celcuity.com/team/manfred-auer-phd/) - Dr. Auer is research professor of chemical and translational biology of the Scottish Universities Life Sciences Alliance at the University of Edinburgh. In his lab, he links basic research and applied science by developing and running new miniaturized target, compound, and technology platforms comprising all steps from design, theoretical and experimental target analysis, high-throughput chemical
- [Richard J. Nigon](https://www.celcuity.com/team/richard-j-nigon/) - Dick is currently senior vice president of Cedar Point Capital, LLC, a private company that raises capital for early-stage companies, where he has served since 2007. Dick has also been a board member for Tactile Systems Technology since September 2012 and Northern Technologies International Corp. since February 2010, including its non-executive chairman of the board
- [Polly Murphy, DVM, PhD](https://www.celcuity.com/team/polly-murphy/) - Polly has over two decades of business development and commercial strategy experience at leading global pharmaceutical companies, including 12 years in leadership positions with increasing responsibility at Pfizer. She is currently chief business officer of Avadel Pharmaceuticals and is a member of Atea Pharmaceuticals’ board of directors. Prior to Avadel she was chief business officer
- [Leo Furcht, MD](https://www.celcuity.com/team/leo-furcht/) - Leo is Allen-Pardee Professor of Cancer Biology and head of the Department of Laboratory Medicine and Pathology at the University of Minnesota and a member of the Division of Molecular Pathology and Genomics. He served as chairman of the board of directors for University of Minnesota Physicians, the medical school practice plan with approximately 700
- [David F. Dalvey](https://www.celcuity.com/team/david-f-dalvey/) - Dave has served as a member of Celcuity’s board of directors since February 2014. Dave has more than 30 years of experience in the fields of corporate finance and venture capital, working primarily with growth-oriented technology and life science businesses. He has over 10 years of corporate finance advisory experience with two national investment banks,
- [Richard Buller, MD, PhD](https://www.celcuity.com/team/richard-buller/) - Richard most recently served as head oncology clinical development and vice president (VP) of translational oncology at Pfizer, Inc., one of the world’s largest pharmaceutical companies, until he retired in 2016. He had previously served as VP of translational medicine at Exelixis, a leading biopharmaceutical company, where he led efforts to study patients selected by

## Categories

- [Uncategorized](https://www.celcuity.com/category/uncategorized/)
~~~

## llms-full

Not found.